HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c
November 8, 2022 4:11 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.
GUIDANCE:
Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of... More
